Navigation Links
R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent
Date:7/23/2009

n blood pressure medications such as ACE inhibitors or diuretics.

"For this patient population, patients who failed biologic therapies, their bones and joints appear to respond to R788, but the objective and subjective components of the ACR and DAS28 scores are incongruent, mainly because the reported subjective placebo response rates were higher than expected," said Elliott Grossbard, M.D., chief medical officer for Rigel. "Nonetheless, R788 is well tolerated and its side effects appear generally manageable, and we look forward to planning our Phase 3 program for R788 with a corporate partner," he added.

    Safety Results Tables
                                              Placebo         100 mg bid
                                              -------         ----------
    N                                            73              146
    ---                                         ---              ---
    Dose Reductions                          N         %        N         %
    ---------------                        ---       ---      ---       ---
    # Had a Dose Reduction                   2        3%       21       14%
    ----------------------                 ---       ---      ---       ---
    Neutropenia (ANC less than 1500)         0        0%        3        2%
    --------------------------------       ---       ---      ---       ---
    Diarrhea, nausea, vomiting,
     dizziness                               1        1%        7        5%
    ---------------------------            ---       ---      ---       ---
    Increase in Blood Pressure (BP)          1        1%        7        5%
    -------------------------------        ---       ---      ---       ---
    ALT or Alkphos Elevation                 0        0%        4        3%
    ------------------------               ---       ---      ---       ---



    TASKi3 Treatment Emergent Adverse Events

      
'/>"/>
SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 2015  NxStage Medical, Inc. (Nasdaq: NXTM ), ... Jeffrey H. Burbank , Chief Executive Officer, will present ... Miami, FL on Wednesday, March 11 th ... event will be made available at http://ir.nxstage.com  at ... NxStage Medical, Inc. (Nasdaq: NXTM ) ...
(Date:3/4/2015)... XBiotech announced today that results from ... moderate to severe plaque psoriasis have been published ... evaluated the potential benefit of MABp1, the Company,s ... (IL-1a). IL-1a is a pro-inflammatory cytokine present in ... The Company claims that blockade of IL-1a can ...
(Date:3/4/2015)... Pa. , March 4, 2015  Results of ... 100 Consecutive Cases Using MarginProbe for Intra-Operative Positive Margin ... poster session at the 32 nd Annual Miami ... study, conducted by Moshe Papa , MD, FACS, ... at Tel Aviv University, reports an analysis of MarginProbe,s ...
Breaking Medicine Technology:NxStage to Present at the Barclays Capital Global Healthcare Conference 2XBiotech Announces Phase II Psoriasis Study Results in JAMA Dermatology 2New Study Shows Breast Re-excision Rates Significantly Reduced in 100 Consecutive Cases 2
... Oct. 24, 2011 Pinnacle Biologics, Inc., a privately ... filed an Orphan Drug Designation (ODD) for their product ... surgery in the treatment of Malignant Pleural Mesothelioma. ... affecting the lining of the lungs. It is a ...
... Liberate Cosmetic Surgery hopes to raise awareness of some ... within the cosmetic surgery industry through the launch of a ... on-going activity on the subject, such as question and answer ... some exciting new initiatives online, that it hopes people from ...
Cached Medicine Technology:Pinnacle Biologics Files for Orphan Drug Designation for PHOTOFRIN® in the Treatment of Patients with Malignant Mesothelioma. 2Pinnacle Biologics Files for Orphan Drug Designation for PHOTOFRIN® in the Treatment of Patients with Malignant Mesothelioma. 3Pinnacle Biologics Files for Orphan Drug Designation for PHOTOFRIN® in the Treatment of Patients with Malignant Mesothelioma. 4Liberate Cosmetic Surgery aims to Highlight Cosmetic Surgery Industry Issues 2
(Date:3/4/2015)... March 04, 2015 TROY Healthcare Solutions ... which provides the ultimate level of security for prescriptions, ... Hilton Houston Plaza Medical Center located at 6633 Travis ... Beginning at 7 AM, TROY Healthcare Solutions will host ... Solutions will offer brief presentations each hour to introduce ...
(Date:3/4/2015)... Smokers across America are the target of ... Smokers' from Aqua-Tine, the new brand that helps you ... to establish a clear point of view for your ... Love Smokers' elevates the Aqua-Tine brand, gives it an ... bold tone of voice that is also genuinely thoughtful ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 Starting February ... LASIK and PRK procedures at their new location in ... Dr. Joseph King and Dr. Gabriel Chu also provide ... in Surrey is named Fraser Valley Cataract and Laser ... accredited by the College of Physicians and Surgeons of ...
(Date:3/4/2015)... " Optrix by Body Glove ” ... Tech Report, which takes a look at the latest ... Scott Steinberg, a special reporter for NewsWatch and a ... viewers how they have an ultra-rugged, waterproof case with ... a major player at the Consumer Electronics Show in ...
(Date:3/4/2015)... CA (PRWEB) March 04, 2015 The ... dialogue and lyrical music, will be performed by the ... Hills Estates, CA, this March 6-22, 2015, on Fridays, ... Center at Peninsula High School (27118 Silver Spur ... one hour before the program or may be purchased ...
Breaking Medicine News(10 mins):Health News:TROY Healthcare to Offer Prescription Solutions that can save a Hospital $100,000 2Health News:TROY Healthcare to Offer Prescription Solutions that can save a Hospital $100,000 3Health News:The Brand Behind The Bold and Provocative Ad Campaign 'We Love Smokers' 2Health News:The Brand Behind The Bold and Provocative Ad Campaign 'We Love Smokers' 3Health News:King LASIK relocates to Surrey, British Columbia 2Health News:A Waterproof Phone Case with an Interchangeable Lens System was Featured on NewsWatch Television on January 30, 2015 2Health News:The New Mel Brooks Musical Young Frankenstein Performance March 6-March 22, 2015, by the Award Winning Drama Department at Peninsula High School, Rolling Hills 2
... Loma Linda University Children,s Hospital (LLUCH) was ... its efforts in giving breastfeeding mothers the information, ... continue breastfeeding their babies. LLUCH is the first ... this status. "Because children,s hospitals have ...
... Pa., Feb. 2 Employers spend more than $13 billion ... - dubbed the world,s number one health threat by the ... are more prone to injury and accidents and incur higher ... a guidepost to help employers address this issue. Health ...
... of Health and Human Services (HHS) Secretary has ... by the Healthcare Information Technology Standards Panel ... documents that harmonize and recommend the technical standards ... records and help support the nationwide exchange of ...
... Feb. 2 Pet advocates are encouraging,pet owners to ... National Pet,Dental Health Month this February. And it ... provider PetFirst Healthcare saw claims,for illnesses related to oral-health ... "Many pet owners don,t place as much ...
... new study makes important new findings on the role ... confirming that the use of estrogen plus progesterone increases ... far more than estrogen-only; suggesting a two-year "safe" period ... that the increased risk for ductal cancers observed in ...
... Improving Formulary Placement of Newer Entrants to ... from HealthLeaders-InterStudy and Fingertip FormularyNASHVILLE, ... HealthLeaders-InterStudy and Fingertip Formulary find that ... expect to reimburse both Bristol-Myers Squibb/AstraZeneca,s Onglyza ...
Cached Medicine News:Health News:LLUCH is First Children's Hospital in Nation to Receive 'Baby-Friendly' Designation 2Health News:Health Advocate Releases Obesity White Paper: Strategies and Programs to Reduce Obesity in the Workplace 2Health News:Health Advocate Releases Obesity White Paper: Strategies and Programs to Reduce Obesity in the Workplace 3Health News:HHS Secretary Recognizes Products of HITSP Standards Work 2Health News:HHS Secretary Recognizes Products of HITSP Standards Work 3Health News:HHS Secretary Recognizes Products of HITSP Standards Work 4Health News:Pet Dental Claims Skyrocket 2Health News:Study identifies potential 'safe period' for hormone replacement use 2Health News:Less Than Two-Thirds of Surveyed Pharmacy Directors Expect to Reimburse Both Onglyza and Alogliptin Once They are Available for the Treatment of Type 2 Diabetes 2Health News:Less Than Two-Thirds of Surveyed Pharmacy Directors Expect to Reimburse Both Onglyza and Alogliptin Once They are Available for the Treatment of Type 2 Diabetes 3
... in 1937 with the Aviator style created ... Luxottica Group's brand portfolio in 1999. Worn ... since day one, Ray-Bans styles are sunglasses ... sunglasses in the world. Characterized by high ...
... manufacturing the Anne Klein brand under license ... are designed for an all-female market. The ... eyewear identifies herself with the typical modern ... who is image-conscious and quality-conscious and loves ...
... in mind, making eyewear that is kid-tough ... Its not surprising that Disney eyewear was ... selling childrens collection from 1997-2003. Part of ... ability to keep pace with todays fashion ...
... frame mounting technology has redefined rimless collections ... taper at the end of each frame ... of the bushing that mounts within the ... a secure fit is created that far ...
Medicine Products: